Safety and Effectiveness of GENOSS® DES in Patients With Multivessel Coronary Artery Disease (GENOSS-MV)

Genoss

Status

Invitation-only

Conditions

Multivessel Coronary Artery Disease

Percutaneous Coronary Intervention

Treatments

Device: GENOSS® DES Sirolimus Eluting Coronary Stent System

Study type

Observational

Funder types

Industry

Identifiers

NCT06168305

2023GR0399

Details and patient eligibility

About

The investigators intend to establish a multicenter prospective observational study by enrolling and tracking patients with multivessel coronary artery disease (MVCAD) using Genoss DES, a device manufactured with pure domestic technology. The study aims to evaluate the efficacy and safety of Genoss DES in MVCAD patients.

Full description

This study is a sponsor-driven clinical trial (SIT) that aims to enroll patients who have undergone treatment for multivessel coronary artery disease using Genoss stents. The study involves collecting data on the clinical and surgical processes of patients and tracking the occurrence of clinical events.

This prospective, multicenter observational study registers patients with acute coronary artery disease who have been treated with GENOSS stents at a total of 8 institutions.

As it is an observational study, the number of subjects is not separately calculated, but the plan is to recruit a total of 1,000 participants during the study registration period.

Enrollment

1,000 estimated patients

Sex

All

Ages

19+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Adults over 19 years of age
Subjects with multivessel coronary artery disease (MVCAD) (However, subject registration is possible even if the treatment area is restenosis or recurrent lesion, including new lesions)
Subjects who underwent percutaneous coronary intervention (PCI) with GENOSS® DES
Research subjects who agree to the research protocol and clinical follow-up plan, voluntarily decide to participate in this clinical study, and give written consent in the informed consent form.

(However, in the case of foreigners, only those who can speak Korean fluently and understand Korean documents such as the consent form are included.)

Test subjects with known hypersensitivity or contraindications to the following drugs or substances: heparin, aspirin, clopidogrel, sirolimus, contrast medium (however, even subjects with hypersensitivity to contrast medium can be controlled by steroids and pheniramine) In this case, registration is possible, but if there is known anaphylaxis, it is excluded)
When balloon angioplasty is performed on a stenotic area, the balloon cannot be expanded.
Those whose remaining life expectancy is less than 1 year
Expecting to become pregnant, pregnant or lactating woman
The patient was admitted to the hospital due to cardiogenic shock and was predicted to have a low chance of survival based on medical judgment.

Subject

If the researcher determines that the product is not suitable for this clinical study or may increase the risks associated with participation in the study.
Foreigners who cannot speak Korean fluently and have difficulty understanding Korean documents